The showdown over Metsera: Pfizer and Novo prepare for a bidding war
Two of the biggest drug companies in the world are preparing for a multibillion-dollar showdown to buy Metsera, after Novo Nordisk’s shock announcement Thursday that it had offered $1.6 billion more...
View ArticleBristol Myers Q3 earnings: Cobenfy anxiety, PD-1xVEGF strategy and MFN
Bristol Myers Squibb didn’t reveal anything earth-shattering in its third-quarter earnings report on Thursday, but rather a handful of smaller updates on its pipeline and negotiations with the Trump...
View ArticleNational Resilience secures $825M in funding; Regeneron details US...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. National Resilience has secured $825 million in debt financing from...
View ArticlePost-Hoc Live: Breaking down the M&A drama between Pfizer, Metsera and Novo
The obesity wars just got spicier. Today, just a month after Pfizer said it would buy Metsera, Novo Nordisk swooped in with its own bid. Metsera says Novo’s offer is “superior.” Pfizer says it’s not...
View ArticleMerck CEO touts Winrevair launch, says he’s looking for deals ‘with urgency’
Merck CEO Rob Davis said on Thursday that the company is assessing ways to bring in new assets “with urgency.” The comments signal Merck’s continued appetite for deals as the company bolsters its...
View ArticleLilly CEO expects more 'noise' as Metsera M&A fight begins
Despite boasting a $1.5 billion sales beat, Eli Lilly’s earnings were overshadowed by its top competitor Novo Nordisk's efforts to usurp Pfizer in a bidding war over clinical-stage obesity biotech...
View ArticleHHS approves 340B rebate model plans for Merck, Bristol Myers and others
HHS has approved applications from eight drugmakers to participate in the government’s pilot program testing a rebate model for certain 340B discounts. The green light from HHS’ Health Resources and...
View ArticleNovo’s Metsera offer could pose a test for Trump's FTC
Novo Nordisk’s surprise $9 billion offer for obesity drugmaker Metsera could be the first major test of how the Trump administration’s FTC grapples with complex pharmaceutical mergers. The bid looks to...
View ArticleGilead sees cell therapy sales decline in Q3
Gilead Sciences said that its cell therapy revenue dropped 11% in the third quarter, compared with a year ago, citing lower demand for its two CAR-T cell therapies, Yescarta and Tecartus. The light...
View ArticleVesper Bio reports early biomarker data for neurodegenerative disease candidate
A Copenhagen-based biotech said its drug candidate has the potential to normalize levels of a key biomarker that is critical in a genetic form of neurodegeneration. A Phase 1b/2a trial was run to...
View ArticlePost-Hoc Live: Meet the scientists behind Baby KJ’s life-saving CRISPR therapy
Earlier this year, researchers in Philadelphia announced they’d developed a custom-made therapy to fix one infant’s rare genetic mutation. The news about Baby KJ opened the possibility of a new model...
View ArticleOrbiMed-backed biotech quickly changes CEOs; Adaptimmune co-founder to lead...
→ Megan McGill has replaced David Lucchino as CEO of Brenig Therapeutics, an OrbiMed-backed neuro biotech that collected a $65 million Series A last summer. Lucchino was hired ...
View ArticleWhat would Metsera bring to Novo Nordisk?
Pfizer’s motivation to buy Metsera is clear: The big pharma wants to plug the hole in its revenues by getting back into obesity, the world’s fastest-growing drug category. Novo Nordisk
View Article4DMT licenses eye gene therapy to Otsuka in Asia-Pacific; Arcus’ $250M offering
Plus, news about Galapagos, Nanobiotix, AstraZeneca, NovaBridge Biosciences, Corbus and Contineum Therapeutics: 👁️ 4D Molecular Therapeutics, Otsuka inks Asia-Pacific deal: The biotech is getting $85...
View ArticleWhy are BridgeBio and Alnylam both seeing strong growth for their heart drugs?
The much-ballyhooed competition between BridgeBio and Alnylam has been less of a tug-of-war and more of a rising-tide-lifts-all-boats scenario. That’s because both companies are hitting the milestones...
View ArticleDrugmakers are having frequent 'most favored nation' talks with White House
The Trump administration's negotiations with large pharma companies are making gradual progress, according to top drugmaker CEOs, though none suggested that a new deal was imminent. On quarterly...
View ArticleFDA commissioner says more 'deregulatory' action coming soon
FDA Commissioner Marty Makary twice this week hinted that the agency will soon take more “deregulatory” action, in addition to the FDA’s recent move to relax biosimilar clinical trial requirements. In...
View ArticleBaby KJ researchers publish FDA interactions as agency eyes new pathway
Academics and biotechs looking at bespoke gene therapies like the one used to treat baby KJ Muldoon now have a trove of new information for navigating a unique FDA approval process. ...
View ArticleHawaii federal judge rules against FDA decision to maintain abortion pill...
A Biden-era FDA decision to keep certain restrictions in place for the abortion pill mifepristone was arbitrary and unlawful, a federal judge in Hawaii ruled. The ruling marks the latest development in...
View ArticlePfizer sues to stop Novo's Metsera takeover attempt
Pfizer is suing to stop Novo Nordisk from throwing a wrench in its acquisition of Metsera, the next-gen obesity biotech that Pfizer said it would buy for ...
View Article